Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 473 - Heterocyclic compounds containing purine ring systems
Patents for C07D 473 - Heterocyclic compounds containing purine ring systems (11,932)
11/2005
11/17/2005US20050255475 Energy transfer dyes, terminators and use thereof
11/17/2005DE10335061B4 Verfahren zur Herstellung von OH-geschützten [4-(2,6-damino-9H-purin-9-yl)-1,3-dioxolan-2-yl]methanol-Derivaten Process for preparing OH-protected [4- (2,6-Damino-9H-purin-9-yl) -1,3-dioxolan-2-yl] methanol derivatives
11/16/2005EP1595882A1 2,6-dihalogeno-8-substituent-purine compound and process for producing the same
11/16/2005EP1594507A2 Novel antiherpes drug combinations
11/16/2005EP1222182B1 Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benozopyrans
11/16/2005EP1218374B1 Pharmaceutically active sulfonamide derivatives
11/15/2005CA2172534C Conformationally locked nucleoside analogues
11/15/2005CA2164847C O6-substituted guanine derivatives, a process for their preparation and their use in treating tumour cells
11/10/2005WO2005105803A2 Purine derivatives as a1 adenosine receptor antagonists
11/10/2005US20050250795 Synthesis of the viricide valomaciclovir stearate in which an acyclic hydroxymethylbutyl acetal derivative is reduced to the alcohol, reacted with an activated amino acid and N-deprotected; one pot reactions; herpes and retroviral infections
11/10/2005US20050250792 Substituted piperidine compounds useful as modulators of chemokine receptor activity
11/10/2005US20050250786 PNA monomer and precursor
11/10/2005US20050250785 PNA monomer and precursor
11/10/2005CA2565037A1 Purine derivatives as a1 adenosine receptor antagonists
11/09/2005EP1592697A1 Nucleoside analogues with apoptosis-inducing characteristics for treating diseases caused by rapidly proliferating cells
11/09/2005EP1066266B1 Cyclin dependent kinase inhibitors
11/09/2005CN1694884A Crystalline solid famciclovir forms i, ii, iii and preparation thereof
11/08/2005US6962921 Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
11/08/2005CA2297294C Phosphonomethoxymethylpurine/pyrimidine derivatives
11/08/2005CA2176392C Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 7 infection
11/03/2005WO2005102321A1 Composition for acceleration of alcohol metabolism or recuperation from fatigue through gluconeogenesis
11/03/2005US20050245546 e.g. cyclopentyl(9-ethyl-8-phenylpurin-6-yl)amine; diuretic; heart failure, chronic renal disease, cirrhosis
11/03/2005US20050245545 administering a xanthine derivative such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine
11/03/2005US20050245523 Heteroaryl derivatives and their use as medicaments
11/03/2005US20050244331 Labeled adenosine for use in positron emission tomography
11/02/2005EP1590359A2 PARTIAL AND FULL AGONISTS OF A sb 1 /sb ADENOSINE RECEPTORS
11/02/2005EP1590340A1 Inhibitors of histone deacetylase
11/02/2005CN1690058A Process for preparing thioguanine
11/01/2005CA2383351C Xanthine derivatives as selective antagonists of a2b adenosine receptors
10/2005
10/27/2005US20050239829 Novel piperidine compound
10/27/2005US20050239827 N-(4-(2,2-difluoro-benzo(1,3)dioxol-5-ylcarbamoyl)-3-hydroxy-phenyl)-4,6-Bis-((3R,5S)-3,5-diamino-piperidin-1-yl)-(1,3,5)triazine-2-amine for example; Gram-positive and Gram-negative strains; retains potency against common antibiotic resistant strains
10/26/2005EP1390368B1 Disubstituted 7,9-guaninium halides as telomerase inhibitors
10/26/2005EP1098870B1 Nitrate salt of Cetirizine
10/26/2005CN1688580A Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors
10/26/2005CN1688579A Condensed pyridines and pyrimidines with TIE2 (TEK) activity
10/26/2005CN1688578A Phosphodiesterase 4 inhibitors
10/26/2005CN1687066A Conjugated polymer material with lateral group possessing function of guanine, preparing process and application
10/25/2005US6958345 syn-N1-(2-hydroxymethylcyclopropylidenemethyl)-cytosine for example; treating HIV, herpes viruses, Epstein-Barr virus (EBV), hepatitis B virus
10/25/2005US6958344 Pyrimidine compounds and their use as modulators of chemokine receptor activity
10/20/2005WO2005097140A2 Selective antagonists of a2a adenosine receptors
10/20/2005WO2005097135A2 Use of 9h-purine-2,6-diamine derivatives in the treatment of proliferative diseases and novel 9h-purine-2,6-diamine derivatives
10/20/2005US20050234077 Pyrimidine compounds and their use as modulators of chemokine receptor activity
10/20/2005US20050234036 3-(2-tetrahydrofuryl-methyl)-2-thioxanthine; neuroinflammatory disorders; pain, cancers, rheumatic arthritis, neurodegenerative diseases
10/20/2005CA2563123A1 Selective antagonists of a2a adenosine receptors
10/20/2005CA2559014A1 Use of 9h-purine-2,6-diamine derivatives in the treatment of proliferative diseases and novel 9h-purine-2,6-diamine derivatives
10/19/2005EP1585735A1 Hydroxamid acid derivatives as histone deacetylase (hdac) inhibitors
10/19/2005EP1401837B1 Purine derivatives as a2b adenosine receptor antagonists
10/19/2005CN1684966A Novel adenine compound and use thereof
10/19/2005CN1683371A Substituted purine and substituted 1, 2, 3-trizole pyrimidine new compound with anti-HIV activity, rpeparing method and use
10/19/2005CN1223594C Process for producing 2, 6-dihalogenopurine
10/13/2005WO2005095357A2 Pyrimidine derivatives and methods of treatment related to the use thereof
10/13/2005WO2005095327A1 Aniline derivatives
10/13/2005WO2005094885A1 Preventive and/or therapeutic agent for disease accompanied by chronic muscle/skeleton pain
10/13/2005US20050228004 administering drugs such as 3-[2-(Cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)imidazo[1,2-a]pyridin-8-amine, for therapy of viral diseases caused by DNA viruses
10/13/2005DE102004012921A1 New 7-butynyl-8-(3-amino-1-piperidinyl)xanthine derivatives useful as dipeptidyl peptidase IV inhibitors, e.g. for treating diabetes, arthritis, obesity and osteoporosis
10/13/2005CA2561383A1 Prophylactic and/or therapeutic agents for chronic musculoskeletal pain
10/13/2005CA2558915A1 Pyrimidine derivatives and methods of treatment related to the use thereof
10/12/2005EP1370568B1 Chemical compounds
10/12/2005EP1177188B1 Pyrazole carboxamides useful for the treatment of obesity and other disorders
10/12/2005EP1150982B1 PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkB-alpha
10/12/2005CN1679612A Enantiomerically pure beta-d-dioxolane nucleosides with selective anti-hepatitus b virus activity
10/12/2005CN1679562A Antiviral compounds
10/12/2005CN1222527C Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease
10/06/2005WO2005092893A1 9-substituted 8-oxoadenine compound
10/06/2005WO2005092892A1 8-oxoadenine compound
10/06/2005WO2005092891A2 Preparation of esters of ganciclovir
10/06/2005WO2005000850B1 Novel crystalline forms of valacyclovir hydrochloride
10/06/2005US20050222413 (Famciclovir); reacting the thallium salt of 2-aminopurine and 2-acetoxymethyl-4-bromobut-1-yl-acetate in a polar organic solvent under mild reaction conditions; selective coupling at the 9-position; by-product inhibition; antiviral drug
10/06/2005US20050222412 Antibiotic; bactericides
10/06/2005US20050222180 Pharmacokinetic properties, including improved oral bioavailability, greater potency and extended effective drug biological half-life in vivo; inhibiting RNA-dependent RNA polymerase, infections
10/06/2005US20050222179 Adenosine receptor antagonists and methods of making and using the same
10/06/2005US20050222178 Process
10/06/2005US20050221390 High quantum yield acridinium compounds and their uses in improving assay sensitivity
10/06/2005CA2559036A1 9-substituted 8-oxoadenine compound
10/05/2005EP1582516A1 Nitrogenous heterocyclic derivative and organic electroluminescent element employing the same
10/05/2005EP1581539A2 Novel tyrosine kinase inhibitors
10/05/2005EP1581220A2 2-nh-heteroarylimidazoles with antibacterial activity
10/05/2005CN1678613A Hetereoaryl nitrile derivatives
10/05/2005CN1678311A Aryl carbonyl derivatives as therapeutic agents
09/2005
09/29/2005WO2005009334A3 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof
09/29/2005US20050215794 Group IB compounds used as condensation, amination, amidation or arylation catalysts; catalysis; efficiency; forming a carbon-carbon bond between a reactant comprising a nucleophilic carbon atom, e.g., enolate or malonate anion, and activated carbon of an aryl, heteroaryl, or vinyl halide or sulfonate
09/29/2005US20050215787 An improved process for the preparation of purines
09/29/2005US20050215568 Substituted oxetanes, method of making, and method of use thereof
09/28/2005EP1579768A1 6-benzyladenine based composition for improving the quali-quantitative appearance of actinidia fruits, use and method of application thereof
09/28/2005EP1578758A2 Purine nucleosides
09/28/2005EP1578722A2 Kinase inhibitor scaffolds and methods for their preparation
09/28/2005EP1210348B1 Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them
09/28/2005CN1675213A 新的嘌呤衍生物 New purine derivatives
09/28/2005CN1675212A 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
09/28/2005CN1675211A 新的嘌呤衍生物 New purine derivatives
09/28/2005CN1675208A Novel fused imidazole derivative
09/27/2005US6949644 Methods for the synthesis of substituted purines
09/27/2005US6949564 NPY-5 antagonists
09/27/2005US6949559 Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
09/27/2005US6949535 for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one
09/27/2005US6949521 Therapeutic azide compounds
09/22/2005WO2005074654A3 Methods to manufacture 1,3-dioxolane nucleosides
09/22/2005US20050209243 7-[2-[4-(2-methoxyphenyl)piperazinyl]-ethyl]-1,3-dimethylxanthine (KMUP-1); muscle relaxants, endothelium-dependent NO releasing, learning and memory activities, erectile dysfunction
09/22/2005US20050209242 Theophylline and 3-isobutyl-1 methylxanthine based N-7 substituted derivatives displaying inhibitory activities on PDE-5 phospodiesterase
09/21/2005EP1575973A2 Substitution derivatives of n sp 6 sp -benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds
1 ... 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 ... 120